Biotech Sarepta Therapeutics (SRPT) got an upgrade and a price target increase Wednesday, a day after it said the FDA had finally accepted its filing for muscular-dystrophy drug eteplirsen. Late Tuesday, Sarepta said the agency had granted eteplirsen priority review and set its deadline for making an approval decision at Feb. 26. The drug treats cases of Duchenne muscular dystrophy (DMD) associated with a genetic mutation of exon 51, which
Overseas markets beckon for U.S. media and entertainment companies amid hand-wringing over the state of the U.S. pay-TV industry. Media companies face cord-cutting and loss of traditional TV subscribers as millennials flock to Web streaming and on-demand viewing. So there’s upside in taking content abroad and investing in untapped markets. “International growth is important as it offsets a slowing U.S. market,” said Michael Nathanson, an analyst
Salesforce.com (CRM) is trying to become a $10 billion company as well as tap into a target-rich environment, and it may well have made huge strides toward both with its announcement Tuesday of plans to offer wealth management services software to the cloud. The big player in cloud customer relationship management software, Salesforce said it will start offering this financial services package — called the Salesforce Financial Services Cloud — as